GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma Read More September 15, 2026
The Real Bottleneck in U.S. Pharma Reshoring Isn’t Factories – It’s Talent Read More September 15, 2026